← Eichor
Study identifier: NCT05536219 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections

Condition: Severe Respiratory Infections  ·  Sponsor: Hospices Civils de Lyon

PhaseN/A
Planned participants360
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Type I interferons (IFN-I) production is induced by the detection of viral molecules, such as RNA or DNA viral strands, through pattern recognition receptors (PRR) present on many immune cell types. Despite a minimal concentration, IFN-I secretion activate the secretion, by neighbouring cells, of more than 700 proteins with antiviral properties (inhibition of viral replication, destabilization of virus membranes, etc.). IFN-I constitute therefore one of the major first line of defence established by the immune system in response to viral infection. Briefly, during the Coronavirus disease (COVID-19) pandemic, several teams including ours, highlighted a lack of IFN-I response in approximately one in five individuals presenting a severe form of COVID-19. Interestingly, within a large part of them, in vitro investigations revealed the presence of autoantibodies presenting neutralizing capacities against alpha and/or omega interferons This finding confirms the deleterious role of anti-IFN-I autoantibodies on the antiviral immune response and the key role of IFN-I pathway regarding defences against COVID-19 infection. Furthermore, those observations pave the way to interesting research that would allow understanding the underlying pathophysiological mechanisms of severe viral respiratory infection. The research hypothesis are: i) IFN-I deficiency could induce severe forms of viral infections which could lead to intensive care admission ii) IFN-I deficiency could increase viral l…

This description comes directly from the study's public registry record.

Talk to the study team

Louis CHAUVELOT, MD  ·  0472071762  ·  louis.chauvelot@chu-lyon.fr

Sophie ASSANT, MD  ·  0472678780  ·  sophie.assant@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (3)

Hôpital Femme Mère et enfantBron, Rhone, FranceRecruiting
Hopital Lyon SudPierre-Bénite, Rhone, FranceRecruiting
Hôpital Croix RousseLyon, Rhône, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05536219